NMI 8000 companion diagnostic - Medical Prognosis Institute
Latest Information Update: 29 Jan 2016
At a glance
- Originator Nemucore Medical Innovations
- Developer Medical Prognosis Institute; Nemucore Medical Innovations
- Class Diagnostic agents
- Mechanism of Action Anti-Mullerian hormone receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II Solid tumours
Most Recent Events
- 29 Jan 2016 Phase-II clinical trials in Solid tumours (Diagnosis) in USA (unspecified route) before January 2016